Side effect On the part of the central nervous system: sedation, somnolence, dizziness, tremor, early dyskinesia (spasmodic torticollis, oculogyric crises, lockjaw), passing in the appointment of the central m-holinoblokatorov halotestin cycle rarely -ekstrapiramidny syndrome and related disorders: akinesia, sometimes combined with muscle hypertonicity and partially eliminated by the appointment of the central m-anticholinergics, hyperkinesia, hypertonicity, motor excitation, akataziya. cases of tardive dyskinesia, characterized by involuntary rhythmic movements mainly language and / or persons with long courses of treatment that can be observed in during the course of treatment by all antipsychotic drugs: the use of antiparkinsonian drugs is not effective or may cause a worsening of symptoms. should be discontinued With the development of hyperthermia drug because increased body temperature may indicate the development of neuroleptic malignant syndrome.
On the part of the endocrine system: may develop reversible hyperprolactinemia, the most common manifestations of which are galactorrhea, amenorrhea, dysmenorrhea, at least – gynecomastia, impotence and frigidity. In excessive sweating can be observed during treatment sulpiride increase body weight. From the digestive system: increased activity of liver enzymes. cardio – vascular system: tachycardia, may increase or decrease in blood pressure, in rare cases may develop orthostatic hypotension, prolongation of the interval QT, very rare cases of «torsade des pointes syndrome . ” On the part of the circulatory and lymphatic systems: hemolytic anemia, aplastic anemia, leukocytosis, thrombocytopenia purpura, granulocytosis. Allergic reactions: possible skin rash.
Experience with overdose is limited sulpiride. Specific symptoms are absent, can be observed: dyskinesia with spastic torticollis, and tongue protrusion lockjaw, blurred vision, increased blood pressure, sedation, nausea, extrapyramidal symptoms, dry mouth, vomiting, excessive sweating, and gynecomastia may develop CSN. . In some patients – parkinsonism
Sulpiride partly removed by hemodialysis.
In the absence of a specific antidote should be used symptomatic and supportive care with careful monitoring of respiratory function and constant monitoring of halotestin cycle cardiac activity (risk of QT interval prolongation), which should continue until the patient’s recovery; holinoblokatory central action is prescribed for the development of extrapyramidal syndrome.
Interactions with other drugs is contraindicated in combination Dopamine receptor agonists (amantadine, apomorphine, bromocriptine, cabergoline, entacapone, lisuride, pergolide, piribedsh, pramipexole, quinagolide, ropinirole), except for patients with Parkinson’s disease. In the dopamine receptor agonists and neuroleptics there is mutual antagonism. When extrapyramidal syndrome induced by neuroleptics are not used dopamine receptor agonists; In such cases use anticholinergics. . Sultoprid Increased risk of ventricular arrhythmias, particularly atrial fibrillation. Not recommended combinations of drugs that can cause ventricular arrhythmias such as «torsade des pointes»: antiarrhythmics class Ia (quinidine, gidrohinidin, disopyramide) and class III (amiodarone, sotapol, dofetilide, Ibutilide), some antipsychotics (thioridazine, chlorpromazine, Levomepromazine, trifluoperazine, tsiamemazin, amisulpride, tiaprid, haloperidol, droperidol, pimozide), and other drugs such as: bepridil, cisapride, difemanil, intravenous erythromycin, mizolastine, intravenous vincamine, etc. .
Alcohol Alcohol increases the sedative effect of neuroleptics. Violation of attention creates a danger for driving and using machinery that require attention. Consumption of alcoholic beverages should be avoided and the use of medicinal products containing alcohol. Levodopa Mutual antagonism between levodopa and neuroleptics. Patients with Parkinson’s disease should be prescribed the lowest effective dose of both drugs. Dopamine receptor agonists (amantadine, apomorphine, halotestin cycle bromocriptine, cabergoline, entacapone, lisuride, pergolide, piribedsh, pramipexole, quinagolide, ropinirole) in patients with Parkinson’s disease. In the dopamine receptor agonists and neuroleptics there is mutual antagonism. The above drugs can cause or exacerbate psychosis. If you need neuroleptic treatment of the patient with Parkinson’s disease and dopamine receptor antagonist receives, the latter should gradually reduce the dose until canceled (abrupt withdrawal of dopamine agonists may lead to the development of neuroleptic malignant syndrome).